Present Title & Affiliation
- Medical Oncologist, Breast Cancer and Cancer Genetics, Centro Paulista de Oncologia (CPO), Oncoclínicas, São Paulo, Brazil
- Attending Physician, Medical Oncology, Grupo Oncoclínicas – Unidade Faria Lima, São Paulo, Brazil
- PhD Candidate, Sírio-Libanês Institute of Education and Research, São Paulo, Brazil
- Clinical Researcher in Hereditary Breast Cancer and Precision Oncology, LACOG/GBECAM Collaborative Network
- Investigator, Brazilian Breast Cancer Gene Database (BBCGENE) Molecular Registry
PUBLICATIONS
1. Nomelini, R. S.; Oliveira, L. J. C.; Jammal, M. P.; Adad, S. J.; Murta, E. F. C.
Serous papillary cystadenocarcinoma in supernumerary ovary. Journal of
Obstetrics and Gynaecology. v.33, p.324. 2013.
https://doi.org/10.3109/01443615.2012.749847
2. Nomelini, R. S.; Oliveira, L. J. C.; Tavares-Murta, B. M.; Murta, E. F. C.
Parameters of blood count and tumor markers: a retrospective analysis and
relation to prognostic factors in ovarian cancer. European Journal of
Gynaecological Oncology. v.38, p.364. 2017. PMID: 29693874
3. Oliveira, LJC; Gongora, ABL; Barbosa, FG; Dos Anjos, CH; Munhoz; RR.
Atypical response with bone pseudoprogression in a patient receiving nivolumab
for advanced cutaneous squamous cell carcinoma. Journal for Immunotherapy
of Cancer. 2018 Nov 27;6(1):130. doi: 10.1186/s40425-018-0444-5.
4. Oliveira, LJC.; Canedo, F. S. N. A.; Sacardo, Karina P; Alessi, João V M;
Barbosa, Felipe G; Shimada, Andrea K; Katz, Artur. Bevacizumab-associated
osteonecrosis of the femur and tibia. Oxford Medical Case Reports. v.2019,
p.235 – 238, 2019.
5. Oliveira, LJC; Gongora, ABL; Latancia, MT; Barbosa, FG; Gregorio, JVAM;
Testagrossa LA; Amano, MT; Feher O. The First Report of molecular
characterized BRD4-NUT carcinoma in Brazil. Journal of Medical Case
Reports. v 13, p 279. 2019. DOI: 10.1186/s13256-019-2213-6
6. Harada, G; Santini, FC; Canedo FSNA; Oliveira LJC; Zuppani HB; De Castro
Jr G. Successful Osimertinib rechallange following drug-induced pneumonitis
after previous anti-PDL1 exposure. Ecancermedicalscience. v. 13, p 970. 2019.
DOI: 10.3332/ecancer.2019.970
7. Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sarcado KP;
Zucchetti BM; Shimada AK; De Galiza Barbosa F; Feher O; Katz A. Alectinib
activity in chemotherapy-refractory metastatic RET-rearranged non-small cell
lung carcinomas: a case series. Lung Cancer (2019). doi:
https://doi.org/10.1016/j.lungcan.2019.10.020 .
8. Gongora, ABL; Oliveira, LJC; Jardins, DLF; Impact of the biomarker
enrichment strategy in drug development. Expert Review of Molecular
Diagnostics, 2019. DOI: 10.1080/14737159.2020.1711734.
9. Oliveira, LJC; Gongora, ABL; Jardins, DLF; Spectrum and Clinical Activity of
PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. Curr
Oncol Rep 22, 70 (2020). https://doi.org/10.1007/s11912-020-00928-5 .
10. Marta GN; Albeesh R; Pereira AAL; Oliveira LJC; Mano MS; Hijal T. The
impact on clinical outcomes of post-operative radiation therapy delay after
neoadjuvant chemotherapy in patients with breast cancer: A multicentric
international study. The Breast. 2020 Aug 29; 54:46-51. doi:
10.1016/j.breast.2020.08.013.
11. Mano MS; Oliveira LJC; Hanna SA. Integrating adjuvant with Post-
neoadjuvant therapies in early breast cancer. Curr Oncol Rep 23, 58 (2021).
https://doi.org/10.1007/s11912-021-01050-w
12. Oliveira LJC; Gongora ABL; Lima FAS; Canedo FSNA; Quirino CV; Pisani
JP; Achatz MI; Rossi BM. Expanding the phenothype of E318K (c.952G>A)
MITF germline mutation carriers: case series and review of the literature.
Hereditary Cancer in Clinical Practice 19, 32 (2021).
https://doi.org/10.1186/s13053-021-00189-8
13. Oliveira, Leandro Jonata Carvalho; Amorim, Larissa Costa; Megid, Thais
Baccili Cury; De Resende, Cristiano Augusto Andrade; Mano, Max S. Gene
expression signatures in early breast cancer: Better together with
clinicopathological features. Critical Reviews in Oncology Hematology. v.175,
p.103708, 2022. https://doi.org/10.1016/j.critrevonc.2022.103708
14. Peixoto, Renata D’Alpino; Oliveira, Leandro Jonata de Carvalho; Passarini,
Thaís de Melo; Andrade, Aline Chaves; Diniz, Paulo Henrique; Prolla, Gabriel;
Amorim, Larissa Costa; Gil, Mariana; Lino, Flora; Garicochea, Bernardo;
J´acome, Alexandre; Kimmie Ng. Vitamin D and colorectal cancer – A practical
review of the literature. Cancer Treatment and Research Communications, v. 32,
2022. https://doi.org/10.1016/j.ctarc.2022.100616
15. Mathias-Machado MC, de Jesus VHF, de Carvalho Oliveira LJ, Neumann M,
Peixoto RD. Current Molecular Profile of Gastrointestinal Stromal Tumors and
Systemic Therapeutic Implications. Cancers (Basel). 2022 Oct 29;14(21):5330.
doi: 10.3390/cancers14215330.
16. Resende CAA, Fernandes Cruz HM, Costa E Silva M, Paes RD, Dienstmann R,
Barrios CHE, Goncalves AC, Cascelli FGA, Souto AKBA, Oliveira LC,
Reinert T, Andrade DAP, Passos MP, Millen EC, Zerwes F, Moraes PL, Ferrari
BL, Mano MS. Impact of the COVID-19 Pandemic on Cancer Staging: An
Analysis of Patients With Breast Cancer From a Community Practice in Brazil.
JCO Glob Oncol. 2022 Nov;8:e2200289. doi: 10.1200/GO.22.00289.
17. Max Senna Mano, Rafaela Gomes, Carlos Barrios, Wanessa Cassimiro
Fernandes, Leandro Jonata Carvalho Oliveira, et al. Subgroup Analysis of
Brazilian Participants of A medical Leadership Competencies Instrument: A
Latin American Cooperative Oncology Group (LACOG) And Academy of
Leadership Sciences Switzerland (ALSS) Study. Brazilian Journal of Oncology,
2022. https://doi.org/10.5935/2526-8732.20220375
18. Oliveira LJC, Megid TBC, Rosa DD, et al. Cost-effectiveness analysis of
Oncotype DX from a Brazilian private medicine perspective: a GBECAM
multicenter retrospective study. Ther Adv Med Oncol. 2022 Dec 26;
14:17588359221141760. doi: 10.1177/17588359221141760.
19. Queiroz MM, Sacardo KP, Ribeiro MF, Gadotti LL, Saddi R, Oliveira LJC, et
al. Real-world treatment outcomes in HR+ HER2- metastatic breast cancer
patients treated with CDK4/6 inhibitors: Results from a reference center in
Brazil. Cancer Treat Res Commun. 2023; 35:100683. doi:
10.1016/j.ctarc.2023.100683. Epub 2023 Jan 19. PMID: 36716534.
20. Menezes TU, Serra MM, Barrios CH, Oliveira LJ, et al. Results of a survey
study on health professionals' perceptions of tumor boards in Brazil. Future
Oncol. 2023 May 24. doi: 10.2217/fon-2023-0158. Epub ahead of print. PMID:
37222176.
21. Reinert T, do Rego FO, Silva MCE, Rodrigues AM, Koyama FC, Gonçalves
AC, Pauletto MM, de Carvalho Oliveira LJ, de Resende CAA, Landeiro LCG,
Barrios CH, Mano MS, Dienstmann R. The somatic mutation profile of estrogen
receptor-positive HER2-negative metastatic breast cancer in Brazilian patients.
Front Oncol. 2024 Jun 17; 14:1372947. doi: 10.3389/fonc.2024.1372947.
PMID: 38952553.
22. Oliveira LJC, Rodrigues AM, Fernandes CB, et al. A portrait of germline
pathogenic variants in high and moderate penetrance breast cancer genes in
Brazil. Front Oncol. 2024 Dec 17; 14:1495605. doi:
10.3389/fonc.2024.1495605.
23. Leandro Jonata Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, Max
S. Mano et al. Cancer outcomes in patients eligible for adjuvant cyclin-
dependent kinase 4 and 6 inhibitors (CDK4/6i) but spared adjuvant
chemotherapy by Oncotype Dx: A multicenter retrospective study (GBECAM
0520). Under review.
24. Jessé Lopes da Silva, Leandro Jonata de Carvalho Oliveira, Cristiano
Augusto Andrade de Resende, Tomas Reinert, Lucas Zanetti de Albuquerque,
Luís Felipe Leite da Silva, Max Senna Mano. Understanding and Overcoming
CDK4/6 Inhibitor Resistance in HR+/HER2– Metastatic Breast Cancer: Clinical
and Molecular Perspectives. Under review.
ARTICLES IN ANNALS OF EVENTS
1. Oliveira LJC; Megid TBC; Sahade M; Shimada AK; Assad DX; Horvat JV;
Assunção AN; Katz A; Mano MS. Prediction of the High-risk Oncotype Dx
recurrence score from clinicopathologic factors: a report from a Cancer
Reference Center in Brazil. San Antonio Breast Cancer Symposium, 2019.
2. Oliveira LJC; Megid TBC; Sahade M; Shimada AK; Assad DX; Lima JMS;
Linck RDM; Pereira AAL; Katz A; Mano MS. Oncotype DX Testing In Early-
stage Breast Cancer And Impact On Chemotherapy Use: A Report From A
Reference Cancer Center In Brazil. 2019. 21 st Brazilian Congress of Clinical
Oncology, 2019, Brazil. Braz J Oncol. 2019;15 (Suppl.1) :1-93.
3. Oliveira LJC, Lima FAS, Gadotti LL, Sahade M, Anjos CH, Testagrossa LA,
Macedo MP, Munho RR. Perfil Molecular de pacientes com melanoma avaliado
por técnica de NGS (Next Generation Sequencing) em uma população brasileira.
2019, 13 th Brazilian Conference of Melanoma, 2019, Brazil.
4. Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sarcado KP;
Zucchetti BM; Shimada AK; De Galiza Barbosa F; Feher O; Katz A. Metastatic
RET-Rearranged Lung Adenocarcinomas Treated with Alectinib: Retrospective
Analysis of a Single Institution. 2019 World Conference on Lung Cancer,
Barcelona.
5. Marta G, Mano MS, Oliveira LJC, Pereira AAL. Analysis of Clinical
Outcomes based on Molecular Subtypes in patients with Breast Cancer that
received Neoadjuvant Chemotherapy. Brazilian Breast Cancer Symposium,
2019. DOI: 10.29289/259453942019V29S1G03.
6. Marta G, Pereira AAL, Oliveira LJC, Filassi Jr, Mano, MS. Comparative
effectiveness of Breast conserving surgery versus mastectomy on survival in
breast cancer patients that received neoadjuvant chemotherapy and post-
operative radiation therapy. Brazilian Breast Cancer Symposium, 2019. DOI:
10.29289/259453942019V29S1G07.
7. Leandro Jonata Carvalho Oliveira, Thais B C Megid, Daniela Dornelles
Rosa, et al. First Results of a Real-World Study Addressing the Potential Impact
of Oncotype Dx Testing on Chemotherapy Indication in Brazil in The Post-
Tailorx And RxPONDER Era. Breast Tumors ID: 101731. Braz J Oncol. 2021;
17(Supl.1): 1-180. III Semana Brasileira da Oncologia, 2021.
8. Max Senna Mano, Rafaela Gomes, Carlos Barrios, Wanessa Cassimiro
Fernandes, Leandro Jonata Carvalho Oliveira, et al. Subgroup Analysis of
Brazilian Participants of A medical Leadership Competencies Instrument: A
Latin American Cooperative Oncology Group (LACOG) And Academy of
Leadership Sciences Switzerland (ALSS) Study. Public Policy, Access,
Pharmacoeconomics and Health Management. ID: 101707. Braz J Oncol. 2021;
17(Supl.1): 1-180. III Semana Brasileira da Oncologia, 2021.
9. Marcello Moro Queiroz, Karina Perez Sacardo, Mauricio Fernando Silva
Almeida Ribeiro, Luiza Lara Gadotti, Rodrigo Saddi, Leandro Jonata
Carvalho Oliveira, et al. Real-World Treatment Outcomes in Metastatic HR+
HER2- Breast Cancer Patients Exposed to CDK4/6 Inhibitors. ID: 101034. Braz
J Oncol. 2021; 17(Supl.1): 1-180. III Semana Brasileira da Oncologia, 2021.
10. Oliveira, Leandro Carvalho; Megid, Thais Baccili Cury; Rosa, Daniela
Dornelles et al. Cost-effectiveness analysis of Oncotype DX from a Brazilian
private medicine perspective: A GBECAM multicenter retrospective study.
Journal of Clinical Oncology. v.40, p.e18822 – e18822, 2022.
11. Garicochea, Bernardo; Christtanini Koyama, Fernanda; Canato Ferracini,
Amanda; De Bustamante Fernandes, Carolina; Souto, Andreza Karine; Bulcao,
Marcela Lima; De Oliveira Nascimento, Ivana Lucia; Branco Neves Silva, Ana
Carolina; Landeiro, Luciana G.; Oliveira, Leandro Carvalho; et al. Genetic
epidemiology of breast cancer (BC) risk genes from a diverse real-world
oncology practice in Brazil. Journal of Clinical Oncology, v.40, p.10594 –
10594, 2022.
12. Resende, Cristiano Augusto Andrade De; Dienstmann, Rodrigo; Barrios, Carlos
H.; Ferrari, Bruno Lemos; Goncalves, Aline Coelho; Cascelli, Fanny; Souto,
Andreza Karine; Costa E Silva, Matheus; Cruz, Heloisa; Oliveira, Leandro
Carvalho; Andrade, Diocesio Alves Pinto De; Millen, Eduardo Camargo;
Zerwes, Felipe; Reinert, Tomas; Moraes, Paulo; Mano, Max S. Impact of the
COVID-19 pandemic on stage at diagnosis of patients with breast cancer: An
analysis of 11,752 patients from Oncoclínicas. Journal of Clinical Oncology,
v.40, p.10559 – 10559, 2022.
13. Thaiana Aragao Santana, Carolina de Bustamante Fernandes, Ana Carolina
Branco Neves Silva, Fernanda Orpinelli Ramos do Rego, Fernanda Christtanini
Koyama, Layla Testa Galindo, Daniela Tiaki Uehara, Matheus Costa e Silva,
Andreza Karine Souto, Leandro Jonata de Carvalho Oliveira, et al. Frequency
and spectrum of CHEK2 variants in a large Brazilian set of germline-tested
patients. Journal of Clinical Oncology 2023 41:16_suppl, e22539-e22539.
14. Leandro J. C. Oliveira, Thais Megid, Daniela Rosa, et al. Real-world
eligibility for adjuvant CDK4/6 inhibitors among patients without genomic risk
for chemotherapy: a GBECAM multicenter retrospective study [abstract]. In:
Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9;
San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):
Abstract nr PO2-16-07.
15. Renata Colombo Bonadio, Leandro J. C. Oliveira, Daniel Batista, et al. The
Utility of Oncotype DX in Grade 1 Hormone Receptor-Positive Early Breast
Cancer: Insights from a Multicentric Real-World Data Study [abstract]. In:
Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9;
San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):
Abstract PO3-17-11.
16. Leandro Jonata Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, et al.
Cancer outcomes from a real-world cohort of patients eligible for adjuvant
CDK4/6 inhibitors but without genomic risk for chemotherapy: A GBECAM
multicenter retrospective study. Journal of Clinical
Oncology 2024 42:16_suppl, 540-540.
17. Leandro Jonata Carvalho Oliveira, Fernanda Orpinelli Ramos do
Rego, Bernardo Garicochea, et al. A portrait of germline pathogenic variants
from a large real-world cohort of Brazilian patients with breast cancer. Journal
of Clinical Oncology 2024 42:16_suppl, 10593-10593.
18. Andreza Karine de Barros Almeida Souto, Thaiana Aragao Santana, Leandro
Jonata Carvalho Oliveira, et al. Co-occurrence of germline pathogenic variants
in a Brazilian cohort of patients with breast cancer. Journal of Clinical
Oncology 2024 42:16_suppl, e22532-e22532.
ORAL PRESENTATION
1. Oliveira LJC; Megid TBC; Sahade M; Shimada AK; Assad DX; Lima JMS;
Linck RDM; Pereira AAL; Katz A; Mano MS. Oncotype DX Testing In Early-
stage Breast Cancer And Impact On Chemotherapy Use: A Report From A
Reference Cancer Center In Brazil. 2019. 21 st Brazilian Congress of Clinical
Oncology, 2019, Brazil.
2. Awarded Best Oral Presentation: Neuromuscular immunomediated adverse
events: rare and potentially fatal. 2nd Immuno-Oncology review – São Paulo/SP
– Brazil, November, 2018.
BOOK CHAPTERS
1. Oliveira, LJC; Jardim, DLF. PI3K. Biomarcadores em Oncologia. São Paulo.
2. Capareli, FC; Gongora, ABL; Oliveira, LJC. Classificação Molecular do Câncer Colorretal. In: Pólipos Serrilhados. Thieme Rev inter. 2019.
3. Oliveira, LJC; Borges, AM; Gimenes, DL. Tratamento do Câncer de mama metastático triplo negativo. In: Câncer de Mama: a visão do oncologista para residentes de mastologia. Instituto Oncoclínicas, 2021.
4. Mano, MS; Oliveira, LJC; Liedke, PER; Boukai, A. Curso preparatório para a prova de título de especialista em oncologia clínica – Tumores de mama. Instituto Oncoclínicas, 2021.
5. Oliveira, LJC; Borges, AM; Gimenes, DL. Tratamento do Câncer de mama metastático triplo negativo. In: Câncer de Mama: a visão do oncologista para residentes de mastologia. Instituto Oncoclínicas, 2022.
6. Mano, MS; Oliveira, LJC; Liedke, PER; Boukai, A. Curso preparatório para a prova de título de especialista em oncologia clínica – Tumores de mama. Instituto Oncoclínicas, 2022.
7. Mano, MS; Oliveira, LJC; Liedke, PER; Boukai, A. Curso preparatório para a prova de título de especialista em oncologia clínica – Tumores de mama. Instituto Oncoclínicas, 2023.